Search

UCB SA

Gesloten

SectorGezondheidszorg

170.55 -0.12

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

165

Max

171.15

Belangrijke statistieken

By Trading Economics

Inkomsten

857M

Verkoop

3.4B

K/W

Sectorgemiddelde

31.06

39.564

Dividendrendement

0.83

Winstmarge

25.498

Werknemers

9,052

EBITDA

1.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.83%

2.40%

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.4B

32B

Vorige openingsprijs

170.67

Vorige sluitingsprijs

170.55

Nieuwssentiment

By Acuity

50%

50%

157 / 376 Rangschikking in Healthcare

UCB SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jul 2025, 15:46 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Marktinformatie

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Winsten

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Marktinformatie

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Marktinformatie

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Marktinformatie

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Acquisities, Fusies, Overnames

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Marktinformatie

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Marktinformatie

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Belangrijke Marktbewegers

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Marktinformatie
Acquisities, Fusies, Overnames

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Marktinformatie

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Acquisities, Fusies, Overnames

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Acquisities, Fusies, Overnames

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Marktinformatie

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

UCB SA Prognose

Koersdoel

By TipRanks

19.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 94.86Ā EURĀ  19.23%

Hoogste 125Ā EUR

Laagste 74Ā EUR

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor UCB SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

1

Hold

2

Sell

Sentiment

By Acuity

157 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.